Skip to main content

Table 1 Risk adjustment model adopted among men with PCa from clinical registries in Victoria

From: Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia

Variable NCCN
Low Clinical T1–T2a stage AND GS 2–6 AND PSA level <10 ng/mL
Intermediate Clinical T2b–T2c stage OR GS = 7 OR PSA level 10–20 ng/mL
High Clinical T3a stage OR GS 8–10 OR PSA level >20 ng/mL
Very high (locally advanced) Clinical T3b–T4 Any T, N1
Metastatic Any T, Any N, M1
  1. NCCN, National Comprehensive Cancer Network; GS, Gleason Score; PSA, Prostate Specific Antigen